Lomustine + Romiplostim
Phase 2Withdrawn 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
First Progression of MGMT Promoter-methylated Glioblastoma
Conditions
First Progression of MGMT Promoter-methylated Glioblastoma
Trial Timeline
Sep 13, 2022 → Dec 19, 2022
NCT ID
NCT04933942About Lomustine + Romiplostim
Lomustine + Romiplostim is a phase 2 stage product being developed by Amgen for First Progression of MGMT Promoter-methylated Glioblastoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04933942. Target conditions include First Progression of MGMT Promoter-methylated Glioblastoma.
What happened to similar drugs?
3 of 7 similar drugs in First Progression of MGMT Promoter-methylated Glioblastoma were approved
Approved (3) Terminated (1) Active (4)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
🔄Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04933942 | Phase 2 | Withdrawn |
Competing Products
12 competing products in First Progression of MGMT Promoter-methylated Glioblastoma